141 related articles for article (PubMed ID: 9846359)
1. Vaccination against intracellular bacterial pathogens.
Pang T
Trends Microbiol; 1998 Nov; 6(11):433. PubMed ID: 9846359
[No Abstract] [Full Text] [Related]
2. Efficacy of Vi polysaccharide vaccine against strains of Salmonella typhi: reply.
Keddy KH; Klugman KP; Robbins JB
Vaccine; 1998; 16(9-10):871-2. PubMed ID: 9682329
[No Abstract] [Full Text] [Related]
3. Efficacy of Salmonella typhi Vi capsular polysaccharide vaccine in South Africa.
Arya SC
Vaccine; 1997 Feb; 15(2):244. PubMed ID: 9066045
[No Abstract] [Full Text] [Related]
4. Specific and cross-reactive immune response to oral Salmonella Typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly.
Pakkanen SH; Kantele JM; Savolainen LE; Rombo L; Kantele A
Vaccine; 2015 Jan; 33(3):451-8. PubMed ID: 25433216
[TBL] [Abstract][Full Text] [Related]
5. Vi polysaccharide-protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?
Pulickal AS; Pollard AJ
Expert Rev Vaccines; 2007 Jun; 6(3):293-5. PubMed ID: 17542742
[No Abstract] [Full Text] [Related]
6. A Salmonella typhi Vi conjugate vaccine.
Koul PA
N Engl J Med; 2001 Aug; 345(7):545-6. PubMed ID: 11519517
[No Abstract] [Full Text] [Related]
7. Persistence of antibody titres three years after vaccination with Vi polysaccharide vaccine against typhoid fever.
Tacket CO; Levine MM; Robbins JB
Vaccine; 1988 Aug; 6(4):307-8. PubMed ID: 3188615
[TBL] [Abstract][Full Text] [Related]
8. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children.
Mai NL; Phan VB; Vo AH; Tran CT; Lin FY; Bryla DA; Chu C; Schiloach J; Robbins JB; Schneerson R; Szu SC
N Engl J Med; 2003 Oct; 349(14):1390-1. PubMed ID: 14523155
[No Abstract] [Full Text] [Related]
9. Virulence and immunogenicity of galactose-resistant variants of Salmonella typhi Ty21a.
Saxena M; Percheson PB; Di Fabio JL
J Infect Dis; 1993 Aug; 168(2):522-3. PubMed ID: 8336003
[No Abstract] [Full Text] [Related]
10. [The problem of designing typhoid vaccines].
Tymchuk SN; Boĭchenko MN; Vorob'ev AA
Zh Mikrobiol Epidemiol Immunobiol; 1996; (4):86-90. PubMed ID: 9027185
[No Abstract] [Full Text] [Related]
11. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever.
Klugman KP; Gilbertson IT; Koornhof HJ; Robbins JB; Schneerson R; Schulz D; Cadoz M; Armand J
Lancet; 1987 Nov; 2(8569):1165-9. PubMed ID: 2890805
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of active component US military personnel against Salmonella Typhi.
Porter CK; Sorrell T; Mitra I; Riddle MS
Vaccine; 2017 Mar; 35(14):1742-1748. PubMed ID: 28268075
[TBL] [Abstract][Full Text] [Related]
13. Efficient vaccination strategy against typhoid fever.
Arya SC
Vaccine; 2000 May; 18(22):2321-2. PubMed ID: 10905949
[No Abstract] [Full Text] [Related]
14. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever.
Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D
Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a new Salmonella Typhi Vi polysaccharide vaccine--vax-TyVi--in Cuban school children and teenagers.
Azze RF; Rodríguez JC; Iniesta MG; Marchena XR; Alfonso VM; Padrón FT
Vaccine; 2003 Jun; 21(21-22):2758-60. PubMed ID: 12798615
[TBL] [Abstract][Full Text] [Related]
16. Intradermal typhoid vaccination by jet injection.
Dimache G
Ann Sclavo Collana Monogr; 1986; 3(1-2):157-63. PubMed ID: 3426873
[No Abstract] [Full Text] [Related]
17. Review of current typhoid fever vaccines, cross-protection against paratyphoid fever, and the European guidelines.
Zuckerman JN; Hatz C; Kantele A
Expert Rev Vaccines; 2017 Oct; 16(10):1029-1043. PubMed ID: 28856924
[TBL] [Abstract][Full Text] [Related]
18. Multicenter study for the evaluation of the antibody response against salmonella typhi Vi vaccination (EMPATHY) for the diagnosis of Anti-polysaccharide antibody production deficiency in patients with primary immunodeficiency.
Sánchez-Ramón S; de Gracia J; García-Alonso AM; Rodríguez Molina JJ; Melero J; de Andrés A; García Ruiz de Morales JM; Ferreira A; Ocejo-Vinyals JG; Cid JJ; García Martínez JM; Lasheras T; Vargas ML; Gil-Herrera J; García Rodríguez MC; Castañer JL; González Granado LI; Allende LM; Soler-Palacin P; Herráiz L; López Hoyos M; Bellón JM; Silva G; Gurbindo DM; Carbone J; Rodríguez-Sáinz C; Matamoros N; Parker AR; Fernández-Cruz E;
Clin Immunol; 2016 Aug; 169():80-84. PubMed ID: 27236002
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
Mitra M; Shah N; Ghosh A; Chatterjee S; Kaur I; Bhattacharya N; Basu S
Hum Vaccin Immunother; 2016 Apr; 12(4):939-45. PubMed ID: 26901576
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
Kim YR; Yoo JH; Hur JK; Kang JH; Shin WS; Kang MW
J Korean Med Sci; 1995 Oct; 10(5):314-7. PubMed ID: 8750055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
